Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Response-guided sofosbuvir + velpatasvir duration study in genotype 3 chronic hepatitis C with cirrhosis
2016-000599-87Phase 4Terminated
- Sponsor
- Queen Mary University of London
- Start
- Apr 2016
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of velpatasvir and sofosbuvir in chronic hepatitis C (CHC) (2 arms), sponsored by Queen Mary University of London. Primary endpoint: SVR12. Started Apr 2016; status: terminated.
02
Drugs
velpatasvirsofosbuvir
03
Conditions
chronic hepatitis C (CHC)
Beyond the preview
Go deeper on 2016-000599-87.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000599-87.